Our Two Founders
Dr. Mang Yu incorporated NexBio in August 2002 after conceiving our first
product, Fludase®, a First-In-Class medicine for influenza. Dr. Fang Fang
joined NexBio as co-founder in August 2003 when NexBio started operations.
Dr. Mang Yu incorporated NexBio in August 2002 after conceiving our first
product, Fludase®, a First-In-Class medicine for influenza. Dr. Fang Fang
joined NexBio as co-founder in August 2003 when NexBio started operations.
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
Mang Yu, Ph.D., President & Chief Executive Officer (CEO) Dr. Yu is a
scientist entrepreneur. He is a semifinalist of the 20th San Diego
"Entrepreneur of the Year" in 2007. His present company, NexBio, is a
winner of a ~$50M NIH contract and was awarded the “Scientific American
50” for its innovative influenza medicine. Prior to founding NexBio, Dr. Yu
was a co-founder & Executive Vice President of Perlan Therapeutics, a
biopharmaceutical company focusing on the development of treatments for
the common cold. While at Perlan, Dr. Yu successfully raised multiple
rounds of venture capital that supported the company’s development of
ColdSol(TM). Under his leadership, ColdSol(TM) won the Most Innovative
New Product (MIP) Award in 2002. Prior to Perlan, Dr. Yu was a scientific co-
founder of Immusol, Inc. where he served as Director of HIV Gene Therapy,
and later as Director of Target Discovery & Gene Therapy (for HIV, HBV, &
HCV). While at Immusol, Dr. Yu was responsible for a corporate partnership
with Pfizer on an anti-HIV drug, MY-2. Before his immigration to the US in
1985, Dr. Yu was teaching biochemistry for medical students at Fudan
University. He is a frequent guest speaker on bio-entrepreneurship for an
MBA class at San Diego State University. Among other activities, he is a
board member of Bridgetech Holding International, a publicly traded multi-
national healthcare company. Dr. Yu has published his scientific work
extensively and holds numerous patents on anti-viral products. Dr. Yu holds
a Ph.D. degree in Biochemistry & Molecular Biology from the Indiana
University School of Medicine, and completed his post-doctoral training at the
University of California, San Diego.
Fang Fang, M.D., Ph.D., Chief Scientific Officer (CSO) & Chief Medical
Officer (CMO) Dr. Fang co-founded NexBio in 2003, and currently leads all
research and development efforts. She has been named one of the "People
to Watch" in the Life Sciences Industry. Prior to founding NexBio, Dr. Fang
was the Scientific Founder of Perlan Therapeutics, where she was the
inventor of Perlan’s lead drug, ColdSol(TM). At Perlan she held three
positions of increasing responsibility from 1998 to 2003: Scientific & Medical
Director, Vice President of Research & Development, and Chief Scientific
Officer. In addition to receiving the Most Innovative New Product (MIP) Award
for ColdSol(TM) in 2002, Dr. Fang was the 2003 recipient of the “Biopharma
Award for Technology Innovation & Leadership,” was named as one of the
"10 San Diego Innovators of the Next Generation Technology Leadership" in
the same year, and was one of the five finalists for the “Chief Scientist of the
Year" award for bioFUSION 2003. Dr. Fang has been awarded numerous
grants from the National Institute for Allergy and Infectious Diseases (NIAID).
She is a Managing Editor of "Frontiers in Bioscience". Dr. Fang holds a M.D.
degree from Peking Union Medical College, and completed her residency at
Harvard University’s Massachusetts General Hospital in Pathology. In
addition, she holds a Ph.D. degree in Cell Biology from University of
California, San Diego, and completed her post-doctoral training at the
Burnham Institute. From 1995 to 1997, she was a physician scientist at the
Salk Institute.
scientist entrepreneur. He is a semifinalist of the 20th San Diego
"Entrepreneur of the Year" in 2007. His present company, NexBio, is a
winner of a ~$50M NIH contract and was awarded the “Scientific American
50” for its innovative influenza medicine. Prior to founding NexBio, Dr. Yu
was a co-founder & Executive Vice President of Perlan Therapeutics, a
biopharmaceutical company focusing on the development of treatments for
the common cold. While at Perlan, Dr. Yu successfully raised multiple
rounds of venture capital that supported the company’s development of
ColdSol(TM). Under his leadership, ColdSol(TM) won the Most Innovative
New Product (MIP) Award in 2002. Prior to Perlan, Dr. Yu was a scientific co-
founder of Immusol, Inc. where he served as Director of HIV Gene Therapy,
and later as Director of Target Discovery & Gene Therapy (for HIV, HBV, &
HCV). While at Immusol, Dr. Yu was responsible for a corporate partnership
with Pfizer on an anti-HIV drug, MY-2. Before his immigration to the US in
1985, Dr. Yu was teaching biochemistry for medical students at Fudan
University. He is a frequent guest speaker on bio-entrepreneurship for an
MBA class at San Diego State University. Among other activities, he is a
board member of Bridgetech Holding International, a publicly traded multi-
national healthcare company. Dr. Yu has published his scientific work
extensively and holds numerous patents on anti-viral products. Dr. Yu holds
a Ph.D. degree in Biochemistry & Molecular Biology from the Indiana
University School of Medicine, and completed his post-doctoral training at the
University of California, San Diego.
Fang Fang, M.D., Ph.D., Chief Scientific Officer (CSO) & Chief Medical
Officer (CMO) Dr. Fang co-founded NexBio in 2003, and currently leads all
research and development efforts. She has been named one of the "People
to Watch" in the Life Sciences Industry. Prior to founding NexBio, Dr. Fang
was the Scientific Founder of Perlan Therapeutics, where she was the
inventor of Perlan’s lead drug, ColdSol(TM). At Perlan she held three
positions of increasing responsibility from 1998 to 2003: Scientific & Medical
Director, Vice President of Research & Development, and Chief Scientific
Officer. In addition to receiving the Most Innovative New Product (MIP) Award
for ColdSol(TM) in 2002, Dr. Fang was the 2003 recipient of the “Biopharma
Award for Technology Innovation & Leadership,” was named as one of the
"10 San Diego Innovators of the Next Generation Technology Leadership" in
the same year, and was one of the five finalists for the “Chief Scientist of the
Year" award for bioFUSION 2003. Dr. Fang has been awarded numerous
grants from the National Institute for Allergy and Infectious Diseases (NIAID).
She is a Managing Editor of "Frontiers in Bioscience". Dr. Fang holds a M.D.
degree from Peking Union Medical College, and completed her residency at
Harvard University’s Massachusetts General Hospital in Pathology. In
addition, she holds a Ph.D. degree in Cell Biology from University of
California, San Diego, and completed her post-doctoral training at the
Burnham Institute. From 1995 to 1997, she was a physician scientist at the
Salk Institute.
Channel 10/ABC NEWS
Broadcasts a Live
Interview with Dr. Fang
Fang, NexBio's CSO in
Response to President
Bush's $7.1 B Flu Plan
Broadcasts a Live
Interview with Dr. Fang
Fang, NexBio's CSO in
Response to President
Bush's $7.1 B Flu Plan
ABC/Channel 10 NEWS
Features NexBio and
Fludase (watch the 2.2
min. TV news here by
clicking on this link).
Features NexBio and
Fludase (watch the 2.2
min. TV news here by
clicking on this link).
Founders
